Our exciting virtual symposium is now on demand! On April 21, 2022 leading scientists from industry and academia discussed some of the most valuable immunology and oncology research tools available to date: humanized mouse models. Learn how these robust, transitionally relevant mouse models are rapidly changing preclinical drug development in ways we never thought possible.

View On-Demand

AGENDA

 

12:00 PM ET | Opening Remarks

  • Mark Moore, Ph.D., GemPharmatech

12:10 PM ET | Accelerating Drug Development with Genetically Engineered Mouse Models

  • Mark Moore, Ph.D., GemPharmatech
  • Santi Chen, Ph.D., GemPharmatech

12:40 PM ET | Exploiting the Immune-Modulatory Effects of PI3K/mTOR Inhibitors to Remodel the Tumor Microenvironment in Uterine Leiomyosarcoma

  • Wout de Wispelaere, University of Leuven/Flemish Institute for Biotechnology (KU Leuven/VIB)

1:10 PM ET | Using the CD34+ HSC-Humanized NCG Mouse for Oncology Drug Discovery

  • Robert (Bob) Mihalek, Ph.D., Charles River Laboratories

1:40 PM ET | HuCD34-NCG Mice for COVID-19 Research

  • Rúbens Alves, MSc, Ph.D., LaJolla Institute for Immunology

2:10 PM ET | Cancer Immunotherapy: Better Preclinical Candidate Selection Using the Full Advanced Human Immune System Mouse Models

  • Sebastien Tabruyn, Ph.D., TransCure bioServices

2:40 PM ET | Q&A with Presenters Moderated by Stephanie Butler, Senior Conference Director of Fierce Life Sciences 

  • Moderator: Stephanie Butler, Fierce Life Sciences
  • Mark Moore, Ph.D., GemPharmatech
  • Santi Chen, Ph.D., GemPharmatech
  • Wout de Wispelaere, University of Leuven/Flemish Institute for Biotechnology (KU Leuven/VIB)
  • Robert (Bob) Mihalek, Ph.D., Charles River Laboratories
  • Rúbens Alves, MSc, Ph.D., LaJolla Institute for Immunology
  • Sebastien Tabruyn, Ph.D., TransCure bioServices

3:00 PM ET | Closing Remarks

  • Mark Moore, Ph.D., GemPharmatech